skynesher/E+ via Getty Images
- Psyence Biomedical (NASDAQ:PBM) said on Friday that it has received a letter from Nasdaq, notifying the company that it had not regained compliance with the Market Value of Listed Securities requirement for continued listing.
- Unless the company timely requests a hearing before a Hearings Panel, the company’s securities would be subject to suspension or delisting.
- Psyence Biomedical (PBM) said it intends to timely request a hearing before the panel. The hearing request will automatically stay any suspension or delisting action pending the hearing.
